1. Home
  2. NTLA vs CPRI Comparison

NTLA vs CPRI Comparison

Compare NTLA & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

SELL

Current Price

$11.36

Market Cap

1.6B

Sector

Health Care

ML Signal

SELL

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

SELL

Current Price

$21.01

Market Cap

1.8B

ML Signal

SELL

Company Overview

Basic Information
Metric
NTLA
CPRI
Founded
2014
1981
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2016
2011

Fundamental Metrics

Financial Performance
Metric
NTLA
CPRI
Price
$11.36
$21.01
Analyst Decision
Buy
Buy
Analyst Count
20
15
Target Price
$23.11
★ $23.17
AVG Volume (30 Days)
★ 4.9M
3.5M
Earning Date
11-17-2026
10-30-2026
Dividend Yield
N/A
N/A
EPS Growth
27.43
★ 111.40
EPS
N/A
★ 0.85
Revenue
$67,671,000.00
★ $3,474,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$143.36
$2.45
P/E Ratio
★ N/A
$24.98
Revenue Growth
★ 16.92
N/A
52 Week Low
$7.95
$12.40
52 Week High
$18.48
$28.27

Technical Indicators

Market Signals
Indicator
NTLA
CPRI
Relative Strength Index (RSI) 52.25 81.01
Support Level $11.26 $16.82
Resistance Level $13.50 $21.98
Average True Range (ATR) 0.81 0.81
MACD 0.05 0.55
Stochastic Oscillator 51.49 97.55

Price Performance

Historical Comparison
NTLA
CPRI

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 600 company-owned stores, wholesale partners, and online. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold through third-party retailers, e-commerce platforms, and in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

Share on Social Networks: